Compare DoorDash Inc (DASH) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs Sanofi SA — how do they compare? DoorDash Inc trades at $192.53 (market cap $82.86B), while Sanofi SA trades at $40.26 (market cap $96.81B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays a 6.02% dividend while DoorDash Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DoorDash Inc for 59 Days and Sanofi SA for 94 Days on average.
| DASH | SNY | |
|---|---|---|
Market Cap | $82.86B | $96.81B |
Volume | 2,006,669 | 2,081,815 |
Sector | Media | Health |
52-Week High | $275.44 | $52.34 |
52-Week Low | $146.60 | $39.51 |
Typical Hold Time | 59 Days | 94 Days |
Enterprise Value | $80.82B | $116.20B |
Dividend Yield | — | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $191.71, down 0.99% on the day, with strong analyst support showing 75% buy ratings and a $255.80 consensus price target. The company demonstrates robust revenue growth from $6.6B in 2022 to $13.7B in 2025, achieving profitability with net income of $935M. Recent innovations include AI-powered text ordering and drone delivery expansion, though mixed quarterly earnings and a fraud investigation present near-term headwinds.
The outlook remains positive given DoorDash's market leadership and expansion into retail delivery, but investors face risks from competitive pressures, regulatory scrutiny, and elevated valuation multiples. With current price near analyst targets and technical indicators showing bullish momentum, the stock offers growth potential balanced against execution risks in a competitive delivery market.
Sanofi (SNY) trades at $40.23, up 1.69% with recent earnings beats and strong revenue growth to $46.72B in 2025. The stock shows bearish technical signals but maintains solid fundamentals with a 22.2 P/E ratio and 72.77% gross margin. Recent expansion of the Regeneron immunology alliance represents significant strategic positioning for future growth beyond Dupixent.
While near-term technical pressure exists, SNY's fundamental strength and pipeline development provide long-term upside potential. Key risks include patent expiration concerns and competitive pressures in the pharmaceutical sector. Analyst consensus leans slightly positive with 44% buy ratings, though institutional sentiment remains cautious given technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
